Here, we will examine the scientific literature to learn what is known about Sermorelin & Ipamorelin Blend.
hGH: What is it?
Growth hormone is secreted by the pituitary gland is growth hormone. Ghrelin and other growth hormone-releasing peptides (GHRPs), together with growth hormone-releasing hormone (GHRH), appear to trigger its secretion. Another hormone called somatostatin is also considered to be released to prevent growth hormone secretion. Two substances may promote growth hormone release, and another may inhibits it; this is only a small portion of the route indicating the intricate control of growth hormone (GH). These chemicals regulate the organism’s growth hormone (GH) production as a trio. Growth hormone hGH bypasses this feedback mechanism, putting the research models at risk for adverse consequences.
“The master gland” is a popular term for the pituitary gland. Its potential capacity to manufacture and disperse hormones, which serve several organism functions, is considered to diminish over time. Hormone growth regulator levels may fall precipitously after the first years of life. Upon maturating, research suggests a 14% yearly loss and as much as a 50% decrease every seven years. This, together with the hypothalamus’s declining ability to make GHRH and the pituitary’s declining reactivity to GHRH, may explain why growth hormone shortage is an unavoidable consequence of cell aging and physiological decline.
What Is the Function of Growth Hormone?
After peaking early, growth hormone (GH) levels start to decline. In response to growth hormone, the liver secretes more insulin-like growth factor-1. Studies suggest that muscle, bone, and organ cells may all be stimulated to develop by IGF-1 as it circulates in the blood. The following are hypothesized to occur when growth hormone secretion increases, leading to a rise in IGF-1:
- Muscle cell development
- Using fat cell stores as fuel
- Development of bone mass and density
- Enhancing the maturation of the testicles and triggering the release of sex hormones in both male and female species
- Fortifying cardiac function
- Promoting a greater skin structure
- Impacting cognitive processes and episodic memory
The relationship between growth hormone’s roles, the natural decline in hormone levels over time, and the manifestation of age-related illnesses is considered to follow naturally. Because of this, studies investigating peptides’ potential as anti-aging compounds within dividing cells are still in their early stages.
Sermorelin Peptide: What is it?
Studies suggest that Sermorelin may potentially aid the organism in secreting growth hormone-releasing hormone (GHRH). It does not belong to the hGH family of hormones. GHRH contains the first 29 protein-building amino acids or Sermorelin. Nobel laureates R. Guillemin and A. Shalley discovered in the 1970s that 29 amino acids stimulate the pituitary gland’s generation and release of growth hormone.
According to Walker, the pituitary gland is a cluster of specialized cells in the brain that secretes growth hormone (GH). Research indicates that Sermorelin may trigger this release. In contrast to growth hormone, the organism’s natural mechanisms for regulating hormone levels seem unaffected when a growth hormone secretagogue is presented. After six months of Sermorelin nightly, researchers from the University of Washington measured the rise in IGF-1 to verify that the compound was effective. According to Hersch and Merriam (2008), there appeared to be a 35% increase in IGF-1 levels.
Investigations purport that Sermorelin may have anti-aging potential upon cells since it seems to increase the circulation of IGF-1 levels and stimulate the secretion of GH. Some hypothesized properties of Sermorelin may include:
- A potential increase in metabolic rate
- Possible preservation of muscular mass
- Potentially minimal reduction in fat cell storage
- Possible enhancements in immunological response and wound healing
- Perhaps enhanced mineralization and density of bone
- Potentially improved cardiac function
Ipamorelin Peptide: What is it?
Findings imply that it can increase the potential of Sermorelin and Ipamorelin, two growth hormone secretagogues, by acting on separate receptors. It has been hypothesized that Sermorelin may imitate GHRH, while Ipamorelin is believed to imitate ghrelin. When the hunger instinct takes place, the stomach of the organism releases the hormone ghrelin. It has been theorized to raise growth hormone levels by acting on the hypothalamus and the pituitary. In addition to potentially influencing metabolism, inhibiting the breakdown of stored fat cells, and stimulating the production of growth hormone, ghrelin may promote food intake and appetite.
Scientists speculate that the selective release of growth hormone may be induced by Ipamorelin. Studies on the properties of Ipamorelin have suggested the following properties:
- Possible increase in bone density
- Possible weight reduction
- Possible muscle cell development
To review, the pituitary gland secretes growth hormone in response to three hormones, one of which is ghrelin. On the one hand, there is GHRH (Sermorelin). Somatostatin is another hormone that may inhibit growth hormone secretion. Lastly, ghrelin (Ipamorelin) is another hormone that has been theorized to regulate growth hormone secretion; however, it does so via a different receptor.
References
[i] Walker R. F. (2006). Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical interventions in aging, 1(4), 307–308.
[ii] Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. Journal of Clinical Endocrinology and Metabolism. 1991;73(5):1081–1088.
[iii] Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews. 1998;19(6):717–797.
[iv] Russell-Aulet M, Jaffe CA, Demott-Friberg R, Barkan AL. In vivo semiquantification of hypothalamic growth hormone-releasing hormone (GHRH) output in humans: Evidence for relative GHRH deficiency in aging. J Clin Endocrinol Metab. 1999;84:3490
[v] Devesa, J., Almengló, C., & Devesa, P. (2016). Multiple Effects of Growth Hormone in the Body: Is it Really the Hormone for Growth?. Clinical medicine insights. Endocrinology and diabetes, 9, 47–71.
[vi] Walker R. F. (2007). Primary locus intervention: a novel approach to treating age-associated hormone insufficiency. Clinical interventions in aging, 2(4), 495–497.
[vii] Tritos, N & Kokkotou, E. (2006). The Physiology and Potential Clinical Applications of Ghrelin, a Novel Peptide Hormone. Mayo Clin Proc. May 2006;81(5):653-660
[viii] Hersch, E. C., & Merriam, G. R. (2008). Growth hormone (GH)-releasing hormone and GH secretagogues in normal aging: Fountain of Youth or Pool of Tantalus?. Clinical interventions in aging, 3(1), 121–129.
